报告针对早期声门癌的 SBRT 的 I-II 期研究结果。这是一项在单一机构招募 T1 声门癌患者的前瞻性研究。真声带 (TVC) 被分为三部分，第三部分包含疾病，规定 36 Gy 分为 3 个部分。 TVC 中与相关 TVC 相邻的部分计划在 3 个 fx 中接收 30 Gy。 SBRT 通过使用多个弧的基于 LINAC 的方法进行。通过 CTCAE 对毒性进行评分，晚期事件被认为是 SBRT 后 3 个月发生的事件。语音质量通过语音障碍指数（VHI）定期进行调查。计划的样本量为 75 名患者。由于担心晚期毒性，在 33 名患者后停止了应计。 T阶段如下： T1a：23分（69.7%）； T1b：10 分（30.3%）。所有患者均接受了计划治疗，中位随访时间为51.5个月（IQR：47.9-61.0个月）。在最后一次随访中，所有患者均存活且没有疾病证据，但有两名患者因并发原因死亡。 4年局部控制率为100%。 SBRT 中位时间 14.9 个月后，6 名患者 (18.2%) 出现软组织坏死 (N=4) 或软骨坏死 (N=2)。在持续吸烟和/或最近感染过新冠病毒的患者中观察到六分之五的坏死事件。 4 例软组织事件均经保守治疗痊愈。最初恶化后，平均 VHI 评分在 6 个月时较基线显着改善。分 3 次进行 36 Gy 的 SBRT 对于控制 T1 TVC 癌非常有效，但坏死虽然大多是短暂的，但仍令人担忧。根据目前的结果，需要减少总剂量以及更准确的患者选择。版权所有 © 2024。由 Elsevier Inc. 出版。

To report the results of a phase I-II study on SBRT for early glottic cancer.This a prospective study at a single Institution enrolling patients with T1 glottic cancer. The true vocal cords (TVC) were divided into thirds and the third(s) containing disease prescribed 36 Gy in 3 fractions. The portions of the TVCs next to the involved one were planned to receive 30 Gy in 3 fxs. SBRT was delivered by a LINAC-based approach using multiple arcs. Toxicity was scored by CTCAE and late events were considered those occurring 3 months after SBRT. Voice quality was investigated by the voice handicap index (VHI) at regular intervals. The planned sample size was 75 patients.Accrual was discontinued after 33 patients due to concerns for late toxicity. T stage was as follows: T1a: 23 pts (69.7%); T1b: 10 pts (30.3%). All patients received the planned treatment and the median follow-up time is 51.5 months (IQR: 47.9-61.0 months). At last follow up, all patients are alive and without evidence of disease but two patients who died for intercurrent causes. The local control rate is 100% at 4 yrs. Six patients (18.2%) developed soft tissue necrosis (N=4) or cartilage necrosis (N=2) after a median time of 14.9 months from SBRT. Five out of 6 necrotic events were observed in patients who kept smoking and/or had a recent COVID infection. All 4 soft tissue events healed with conservative therapy. After an initial deterioration the average VHI score significantly improved at 6 months over baseline.SBRT to 36 Gy in 3 fractions is highly effective in controlling T1 TVC carcinoma, but necrosis, though mostly transient, is a concern. Based on the present results, a reduction in total dose as well as a more accurate patient selection are warranted.Copyright © 2024. Published by Elsevier Inc.